Articles tagged with: CyBorD
This year’s American Society of Clinical Oncology (ASCO) annual meeting in Chicago ended last Tuesday.
The day before the meeting ended was the busiest day at the meeting with regard to myeloma research. It featured a session of oral presentations in the morning and a poster session in the afternoon. In addition, an education session was held in the afternoon that included one myeloma-related talk, given by Dr. Leif Bergsagel of the Mayo Clinic, about progress in the treatment of multiple myeloma (article in the ASCO 2014 Educational Book). …
Results from a recent, small-scale study conducted at the MD Anderson Cancer Center in Houston suggest that three Velcade-based combination therapies given at lower doses over a short period of time may be safe and effective in newly diagnosed multiple myeloma patients .
In particular, two out of the three combinations showed overall response rates of above 90 percent, and all combinations were associated with few side effects.
Based on their findings, the researchers conclude that the tested combinations are viable alternatives to standard Velcade (bortezomib)-based combinations given over …
Yesterday was the first day of research presentations at this year’s American Society of Hematology (ASH) annual meeting, which is being held in Atlanta.
Research findings related to multiple myeloma was presented in three different sessions during the day.
Two of the sessions were actually the same general educational session about multiple myeloma, repeated at two different times during the day. The Beacon will cover the presentations given during those sessions in a separate daily update.
The key myeloma-related research presented yesterday, however, was made public during a poster session …
Results from a small, retrospective study indicate that combination therapy with Velcade, cyclophosphamide, and dexamethasone may be effective in newly diagnosed myeloma patients with kidney damage.
The findings, discussed in a letter to the editor of the European Journal of Haematology, show that kidney impairment did not worsen in any patients who received the three-drug treatment.
The study investigators also note that side effects were manageable, but recommend further research of the three-drug therapy to determine its safety as a long-term treatment option.
Kidney impairment is a common myeloma-related complication. …
Upfront therapy for newly diagnosed multiple myeloma patients should be risk-adapted and individualized, according to Dr. Vincent Rajkumar from the Mayo Clinic.
Dr. Rajkumar presented his opinions about upfront therapy for myeloma during an education session at the recent annual meeting of the American Society of Clinical Oncology (ASCO). During his presentation, he reviewed the induction treatment options for newly diagnosed multiple myeloma patients and discussed his opinions of the various options.
Induction therapy refers to the initial treatment given to newly diagnosed multiple myeloma patients to combat their cancer. …